Mohamed Fawzy Sheha

Mr. Mohamed Fawzy Sheha

Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
MSMohamed Soltan
Mohamed Soltan
DEDr. Muhammad Alaa Eldeen
Dr. Muhammad Alaa Eldeen
NENada Elbassiouny
Nada Elbassiouny
HKHasnaa Lotfy Kamel
Hasnaa Lotfy Kamel
KAKareem M. Abdelraheem
Kareem M. Abdelraheem
ASAshraf sileem
Ashraf sileem
During the current era of the COVID-19 pandemic, the dissemination of Mucorales has been reported globally, with elevated rates of infection in India, and because of the high rate of mortality and morbidity, designing an effective vaccine against mucormycosis is a major health priority, especially for immunocompromised patients. In the current study, we studied shared Mucorales proteins, which have been reported as virulence factors, and after analysis of several virulent proteins for their antigenicity and subcellular localization, we selected spore coat (CotH) and serine protease (SP) proteins as the targets of epitope mapping. The current study proposes a vaccine constructed based on top-ranking cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and B cell lymphocyte (BCL) epitopes from filtered proteins. In addition to the selected epitopes, β-defensins adjuvant and PADRE peptide were included in the constructed vaccine to improve the stimulated immune response. Computational tools were used to estimate the physicochemical and immunological features of the proposed vaccine and validate its binding with TLR-2, where the output data of these assessments potentiate the probability of the constructed vaccine to stimulate a specific immune response against mucormycosis. Here, we demonstrate the approach of potential vaccine construction and assessment through computational tools, and to the best of our knowledge, this is the first study of a proposed vaccine against mucormycosis based on the immunoinformatics approach.